Original Data

Effects of Pistachio Nut Supplementation on Blood Glucose in Patients with Type 2 Diabetes: A Randomized Crossover Trial

Mahmoud Parham¹, Saeide Heidari², Ashraf Khorramirad², Mohammad Hozoori³, Fatemeh Hosseinzadeh¹, Lida Bakhtyari⁴, Jamshid Vafaeimanesh¹

Manuscript submitted July 14, 2014; resubmitted August 4, 2014; accepted August 7, 2014.

Keywords: type 2 diabetes, pistachio nut, blood glucose, HbA1c, antiglycemic, antiobese

Abstract

BACKGROUND: Diabetes is a chronic, potentially debilitating, and often fatal disease. Dietary strategies to reduce postprandial glycemia are important in the prevention and treatment of diabetes. Nuts are rich in mono- and polyunsaturated fatty acids, which may reduce hyperglycemia and improve metabolism. OBJECTIVES: To evaluate the effectiveness of pistachio nut supplementation on glycemic and inflammatory measures in patients with type 2 diabetes. METHODS: In this double-blind, randomized, placebo-controlled, crossover trial, 48 diabetic patients were equally assigned to groups A and B. Patients in group A received a snack of 25 g pistachio nuts twice a day for 12 weeks and group B received a control meal without nuts. After 12 weeks of intervention, the patients had an 8-week washout. Then the groups were displaced, and group B received the same amount of pistachios for 12 weeks. RESULTS: With respect to the total change in variables over both phases, there was a marked decrease in HbA1c (-0.4%) and fasting blood glucose (FBG) concentrations (-16 mg/dl) in the pistachio group compared with the control group (p ≤ 0.001 for both). There was no overall significant change in BMI, blood pressure, HOMA-IR, and C-reactive protein (CRP) concentrations. Analysis of the two phases separately showed a decrease in FBG by 14 mg/dl and in HbA1c by 0.45% in the treatment group (A) after 12 weeks, while no significant differences were seen in group B (control group). In the second phase, FBG decreased from 151.36 ± 39.22 to 137.28 ± 28.65 mg/dl (-14 mg/dl) and HbA1c decreased from 7.42 ± 0.97 to 7.15 ± 0.68 mg/dl (-0.28%, p = 0.013 and p = 0.033, respectively) in the pistachio group (B). Pistachio consumption reduced systolic blood pressure (p = 0.007), BMI (p = 0.011), and CRP (p = 0.002) in patients from the treatment groups, but not insulin resistance. CONCLUSIONS: Dietary consumption of pistachio nuts as a snack has beneficial effects on glycemic control, blood pressure, obesity, and inflammation markers in diabetic patients.

Fulltext: HTML , PDF (169KB)

This article has been cited by other articles:

	Nut consumption is associated with lower incidence of type 2 diabetes: The Tehran Lipid and Glucose Study Asghari G, Ghorbani Z, Mirmiran P, Azizi F Diabetes Metab 2017. 43(1):18-24
	Phytochemical, ethnomedicinal uses and pharmacological profile of genus Pistacia Rauf A, Patel S, Uddin G, Siddiqui BS, Ahmad B, Muhammad N, Mabkhot YN, Hadda TB Biomed Pharmacother 2017. 86:393-404
	Impact of different types of tree nut, peanut, and soy nut consumption on serum C-reactive protein (CRP): A systematic review and meta-analysis of randomized controlled clinical trials Mazidi M, Rezaie P, Ferns GA, Gao HK Medicine (Baltimore) 2016. 95(44):e5165
	Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review Bodnaruc AM, Prud'homme D, Blanchet R, Giroux I Nutr Metab (Lond) 2016. 13:92
	Updates on Managing Type 2 Diabetes Mellitus with Natural Products: Towards Antidiabetic Drug Development Alam F, Islam MA, Kamal MA, Gan SH Curr Med Chem 2016. In press
	Pistachios for Health: What Do We Know About This Multifaceted Nut? Hernandez-Alonso P, Bullo M, Salas-Salvado J Nutr Today 2016. 51(3):133-138
	Iron Chelating and Antioxidant Activities and Cytotoxicity Effect of the Pistachio (Pistachio vera L.) hull and kernel Extracts in the A549, HT29 and MCF-7 Cancerous Cell lines Dahooee F, Fatemi SJ, Mandegary A, Sharififar F Int J Clin Pharmacol Toxicol 2016. 5(1):195-201
	Effects of pistachios on the lipid/lipoprotein profile, glycemic control, inflammation, and endothelial function in type 2 diabetes: A randomized trial Sauder KA, McCrea CE, Ulbrecht JS, Kris-Etherton PM, West SG Metabolism 2015. 64(11):1521-1529